Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × letermovir × Plasma cell × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 4 Lymphoid 3 Myeloid 2 Plasma cell 1 Dermatologic 1

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 429 Lenalidomide 265 Cyclophosphamide 245 Bortezomib 235 Melphalan 195 Calcium Dobesilate 166 daratumumab 108 fludarabine phosphate 103 Peripheral Blood Stem Cell Transplantation 91 fludarabine 88 carfilzomib 86 pomalidomide 85 Filgrastim 84 Whole-Body Irradiation 81 Thalidomide 81 Mycophenolic Acid 75 Busulfan 69 Granulocyte Colony-Stimulating Factor 64 Tacrolimus 63 ixazomib 57 dexamethasone acetate 57 Cyclosporine 53 dexamethasone 21-phosphate 48 Antilymphocyte Serum 46 auricularum 43 Radiotherapy 39 Stem Cell Transplantation 38 Etoposide 36 isatuximab 32 Bendamustine Hydrochloride 31

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06920251 2025-12-03

OPTIMUS-EL

Seoul National University Hospital

Phase 2 Recruiting

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡